客观缓解率可能是晚期复发性卵巢癌生存期的替代终点
该系统综述纳入39项随机对照试验、共9223例铂敏感和铂耐药复发性卵巢癌患者,评估客观缓解率(ORR)作为生存替代终点的价值。ORR与无进展生存期(PFS)强相关(r=0.85;P<0.0001),加权回归显示ORR每增加10%,PFS增加1.20个月、总生存期(OS)增加2.83个月。作者认为ORR可能是复发性卵巢癌至少二线治疗的OS替代临床试验终点。
要点
- ORR与PFS强相关(r=0.85;P<0.0001),优于疾病控制率(r=0.58;P<0.001)。
- 加权回归显示ORR每增加10%,PFS增加1.20个月、OS增加2.83个月。
- 基于加权数据,替代阈值效应提示ORR需≥1%才能获得非零OS获益。
核心结论
- 该系统综述支持ORR作为复发性卵巢癌至少二线治疗的可能的OS替代临床试验终点。
研究设计与样本
- 系统综述,符合PRISMA标准,检索MEDLINE®和Embase®(2000年至2015年3月23日)并辅以文献目录筛查。
- 纳入报告OS、PFS和ORR的复发性卵巢癌随机对照试验,共39项研究、9223例铂敏感和铂耐药患者。
- 以ORR和疾病控制率为替代指标(自变量),以中位OS和PFS为真实临床结局(因变量),采用相关分析、线性回归和替代阈值效应(STE)对未加权和加权数据进行分析。
主要发现
- ORR(r=0.82;P<0.001)对生存的预测优于疾病控制率(r=0.58;P<0.001),且ORR与PFS强相关(r=0.85;P<0.0001)。
- 加权回归分析显示,ORR每增加10%,PFS增加1.20个月,OS增加2.83个月。
- 对治疗效应(缓解比值比、生存风险比)的回归分析提示,ORR的比值比每增加10%,OS的风险比降低2.5%。
- 基于加权数据,STE提示ORR需≥1%才能获得非零OS获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate literature to assess response rate as a surrogate endpoint of survival in ovarian cancer (OC). METHODS: Systematic review consistent with PRISMA criteria, identified randomized, controlled trials reporting overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in recurrent OC. MEDLINE® and Embase® searches (year 2000-March 23, 2015) were augmented by bibliographic screening. Proposed surrogate measures (independent variables) were ORR and disease control rate. True clinical outcomes (dependent variables) were median OS and PFS. Analyses were performed on unweighted and weighted data using correlation analysis, linear regression, and surrogate threshold effect (STE). Smaller STE indicates greater predictive precision with magnitude of STE dependent on variance of prediction. RESULTS: Thirty-nine studies were included for review, representing 9223 platinum-sensitive and resistant patients. Objective response rate (r=0.82; P<0.001) was a better predictor than disease control rate (r=0.58; P<0.001) and strongly correlated with PFS (r=0.85; P<0.0001). Weighted-regression analysis demonstrated that for each 10% increase in ORR, PFS increased by 1.20months and OS by 2.83months. Regression analysis of treatment effects (odds ratio of response, hazard ratio of survival) suggests that a 10% increase in odds ratio of ORR would result in 2.5% reduction in the hazard ratio of OS. Based on weighted data, STE indicated that an ORR of ≥1% is needed to achieve nonzero OS benefit. CONCLUSION: This systematic review supports ORR as a possible surrogate clinical trial endpoint for OS in recurrent OC with at least second-line therapy.
引用
- Siddiqui MK, Tyczynski J, Pahwa A, et al. Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer. Gynecol Oncol. 2017. PMID: 28395896. doi:10.1016/j.ygyno.2017.03.515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。